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The goals of this study were threefold: to compare the etiology of travelers' diarrhea in
West Africa and Mexico, to evaluate two fecal transport systems for the recovery of en-
teropathogens, and to verify the efficacy of liquid bismuth subsalicylate (BSS) in differ-
ent locations and under different entrance criteria for disease severity. The study popula-
tions consisted of 133 European tourists in West Africa and 112American students in
Mexicowho had suffered from travelers'diarrhea. In 60070 and 38% of the stool samplesat the
two study sites, similar proportions of enteropathogens were detected. A two-vial system
consisting of Enteric Plus medium and polyvinyl alcohol fixative was slightly superior
for identifying enteric pathogens than was a three-vial system with buffered glycerol saline,
Cary-Blair medium with campylobacter antibodies, and polyvinylalcohol fixative. In a par-
allel, double-blind, randomized trial, BSS significantly shortened disease duration at both
study sites.
Travelers' diarrhea is the most frequent health im-
pairment affecting travelers to developing countries
[1]. The fact that clinical symptoms are similar re-
gardless of location suggests common etiologies.
Consequently, agents used for self-therapy should
show a similar efficacy in various countries.
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Previous studies, however, have sometimes dem-
onstrated considerable differences in identified mi-
croorganisms causing travelers' diarrhea in differing
locations [2, 3]. This finding may be due to the spe-
cific populations (military, Peace Corps Volunteers,
students) that wereinvestigated and also to the differ-
ent microbiological assays used. Therefore, this study
was undertaken not only to compare etiologic agents
in two widely different locations, but also to test two
preservation kits for transportation of stool speci-
mens from the field in West Africa to the diagnostic
laboratory for microbiological evaluation. In addi-
tion, the effectivenessof bismuth subsalicylate (BSS),
formerly tested in Latin America [4, 5], was to be
examined not only in a distinctly different geographic
location, but also under different entrance criteria
for disease severity that more closely mimic actual
usage patterns.
Subjects and Methods
Recruitment in West Africa. In West Africa,
adult European tourists of either sex who were stay-
ing at a large hotel either in The Gambia or in Togo
were asked to participate in a double-blind, paral-
lel, randomized study. Recruitment was performed
between November 1985 and February 1986 by a
Swiss medical resident who informed the guests that
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if they developed diarrhea, they should collect a stool
sample and report to a hotel room designated as the
"diarrhea clinic." Diarrhea was defined as one or
more watery (pourable) stools or as one or more
pasty (does not retain its shape) stools accompanied
by nausea, vomiting, or abdominal pain and cramps.
Upon presentation, the resident obtained a signed
informed consent and completed a medical history
on each volunteer. Eligible subjects were randomly
assigned to ingest either 1050mg of BSS liquid ev-
ery 1 h up to a maximum of four doses per day for
two days or a similar-tasting placebo. Medication was
to be started immediately and to be discontinued
when the symptoms subsided. Every subject was
given diary cards to record the time of passage of
each stool, the stool consistency, the severity of asso-
ciated symptoms, side effects, and time and amount
of medication taken during the 0-24- and 24-48-h
treatment periods.
Comparison of fecal transport systems. After
collection, each stool specimen was immediately
placed into two different transport systems for weekly
shipment at room temperature (N23 C) via commer-
cial airline to Houston. The content of these two sys-
tems was as follows: (1) a three-vial system consist-
ing of buffered glycerol saline (BGS), Cary-Blair
medium with campylobacter antibiotics (CB), and
polyvinyl alcohol (PVA) fixative (Remel, Lenexa,
Kan) and (2) a two-vial system consisting of Fekal'"
Enteric Plus medium (modified Cary-Blair medium)
and PYA fixative (Trend Scientific, Minneapolis).
The PYA vials for the identification of parasitic
pathogens were the same in both transport systems
and were not compared. Each specimen from the
Remel two-vial system and the Enteric Plus system
was processed separately for bacterial enteropatho-
gens to determine which system was the best for
transporting fecal specimens. Additionally, for com-
parison with the PYA vial, a sample placed in mer-
thiolate formaline (MF) was forwarded weekly to the
Zurich Institute of Parasitology.
Recruitment in Mexico. In Guadalajara, Mex-
ico, male and female adults (mostly American stu-
dents from the University of Arizona [Tucson], the
University of San Diego [San Diego], or the Univer-
sidad Autonoma de Guadalajara [Guadalajara])
were asked to participate in a double-blind, paral-
lel, randomized three-day efficacy study. From
February to November 1985,prospective participants
were informed that if they developed diarrhea, they
should report to the "diarrhea clinic." Diarrhea was
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defined as one or more symptoms of enteric infec-
tion, plus either three or more unformed stools in
an 8-h period or four or more such stools in a 24-h
period. A stool was obtained. before treatment was
begun, verified as unformed, and processed for en-
teric pathogens at an on-site laboratory.
After informed consent was obtained, each sub-
ject was randomly assigned to use either liquid BSS
according to a two-day regimen of ingesting 525 mg
every 30 min up to a maximum of eight doses per
day or a similar-tasting placebo. Each subject was--
givendiary cards as in WestAfrica and was instructed
to return to the clinic each day. The diary cards were
maintained for 72 h: the 48-h treatment period and
the ensuing 24 h posttherapy.
At both study sites, all subjects who had taken
other antidiarrheal or antimicrobial agents before
or during the surveillance period wereexcluded. Also
excluded were those volunteers who took <750/0 of
the prescribed study medications or took longer than
8 h to complete the total daily dose.
Statistical methods. In the BSS efficacy trial, all
data entries were completed before breaking the
medication code. Statistical evaluation of the data
was performed using the SPSSX® (SPSS Inc.,
Chicago) and SAS® (SAS Institute, Cary, NC) sys-
tems. Survival analysis methods were used to com-
pare disease duration, analysis of variance was used
to compare stool frequencies, and "I: tests were used
to compare stool consistencies. Statistical signifi-
cance was defined as a two-sided a-risk of ~.05. In
the patients still experiencing symptoms at the end
of the surveillance period, the maximum value of
48 h (West Africa) or 72 h (Mexico) was used to cal-
culate the time until improvement or relief.
Microbiology. All stool specimens were inocu-
lated onto MacConkey's, Tergitol-7, and xylose-ly-
sine-desoxycholate (XLD) agars and into selenite-F
enrichment broth (Difco Laboratories, Detroit). These
media were incubated at 37 C for 18h. The selenite-
F broth was then streaked onto a plate of XLD that
was incubated at 37 C for 18 h to enrich Salmonella
and Shigella. Specimens werealso streaked onto thio-
sulfate-citrate-bile-sucrose (TCBS) media (Difco) to
isolate Vibrio spp. A plate of campy-blood agar and
a tube of campylobacter enrichment media (Scott
Laboratories, Houston) were also inoculated and in-
cubated for 24-48 hat 42 C in an atmosphere of 50/0
O2 to isolate Campylobacter jejuni. The enrichment
medium was subcultured to another plate of campy-
blood agar at 24 h.
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Table 1. Enteropathogens identified in pretreatment
stool specimens.
Non-lactose-fermenting colonies from the primary
isolation plates were inoculated onto triple sugar-
iron agar slants and lysine-iron agar slants and into
sulfide-indole-motility media (Difco). Presumptive
enteric pathogens weretested for oxidase production
and were confirmed by using the API 20E system
(Analytab Products, Plainview, NY). Salmonella and
Shigella were serogrouped with commercial typing
antisera (Al-l-Serlmmfiure'"; Analytab), C. jejuni
was identified by gram stain, oxidase test, catalase
test, susceptibility to nalidixic acid, and resistance
to cephalothin. Five Escherichia coli-like colonies
were picked from each specimen and tested for the
production of heat-labile and heat-stable enterotox-
ins (LT and ST, respectively) by using the Y-I adre-
nal cell and suckling mouse assays [6, 7]. E. coli that
did not produce ST or LT were then tested for HEp-2
cell adherence [8], and adherent strains (enteroad-
herent E. coli) were further tested for somatic sero-
groups of enteropathogenic E. coli [8]. Enteroinva-
sive E. coli were detected by biotyping and testing
strains that were lysine decarboxylase negative and
nonmotile in the Sereny test [9] for invasiveness.
Parasitic enteropathogens were sought from the PYA
Study site
Table 2. Comparison of the Remel and Fekal transport
systems for the isolation of bacterial enteropathogens
from diarrheal stool specimens.
13
6
6
9
9
5
1
7
56
Total
8
3
4
3
6
3
1
o
28 (50%)
Both
Fekal
alone
3
3
1
3
o
1
o
6
17 (30%)
Remel
alone
Transport system used
2
o
1
3
3
1
0.
1
11 (20%)
ETEC ST*
ETEC LT*
ETEC ST/LT*
EAEC
Shigella
Salmonella
C. jejuni
Plesiomonas
Total detected
Enteropathogen
isolated
NOTE. All specimens were obtained from European travel-
ers to West Africa. ETEC = enterotoxigenic E. coli; EAEC =
enteroadherent E. coli.
* E. coli from both transport systems were tested for en-
terotoxins only in 66 of the 132 patients.
fixative. Twoslides were prepared, air-dried, and heat
fixed. One slide was stained by using the trichrome
method [10] and was examined microscopically for
fecal leukocytes, Entamoeba histolytica, and Giardia
lamblia. The other slide was stained by using a modi-
fied Kinyoun method for Cryptosporidium [11]. The
MF samples were analyzed by using the method of
Blagg et al. [12],except that iodine was added to the
stool sediment just before exami~ation.Mexico
(n = 112)
West Africa
(n = 132)Enteropathogen isolated
NOTE. Pathogens from the same patient were counted
separately. One sample from West Africa was lost. Data are ex-
pressed as no. of enteropathogens identified (010 of total speci-
mens isolated).
• ETEC = enterotoxigenic E. coli.
ETEC·
ETEC ST
ETEC LT
ETEC STILT
Enteroadherent E. coli
Localized adherence
Diffuse adherence
Enteroinvasive E. coli
Shigella spp.
Salmonella spp.
C. jejuni
Cryptosporidium
Aeromonas spp.
Plesiomonas shigelloides
E. histolytica
G.lamblia
Specimen with pathogens
No agent identified
55 (42)
30
6
19
9 (7)
3
6
o
9 (7)
5 (4)
1 (1)
2 (2)
o
7 (5)
2 (2)
o
79 (60)
53 (40)
27 (24)
9
8
10
7 (6)
1
6
2 (2)
7 (6)
1 (1)
2 (2)
o
1 (1)
o
o
2 (2)
42 (38)
70 (62)
Results
In West Africa, 133 tourists were enrolled, and 130
(67 receiving BSS, 63 receiving placebo) were com-
pletely evaluated. In Mexico, 112 students were re-
cruited, and 99 (49 receiving BSS, 50 receiving pla-
cebo) successfully completed the trial. No significant
differences were found at either study site between
the active medication and the placebo groups with
respect to sex, age, type of malaria prophylaxis, mean
length of illness, number of unformed stools passed,
and other symptoms before therapy.
Microbiology and effectiveness of transport me-
dia. Table 1 shows the enteropathogens isolated
from patients receiving treatment in West Africa and
'Mexico. Enterotoxigenic E. coli were the most com-
mon pathogens isolated in both study locations, al-
though they were identified more frequently in West
Africa (42% vs. 24070). Enteroadherent E. coli and
Shigella were the next most -common pathogens in
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both studies. P shigelloides, E. histolytica, and Cryp-
tosporidium were only identified in West Africa,
whereas G. lamblia, enteroinvasive E. coli, and Aer-
omonas spp. wereonly isolated from patients in Mex-
ico. No enteropathogenic E. coli serotypes were
found in either study. The isolation of bacterial en-
teropathogens from the two transport systems is
given in table 2. The Remel system was more effec-
tive in isolating Shigella and yielded three strains that
were not found using the Fekal system. The Fekal
system identified six P shigelloides isolates, whereas
the Remel system detected only obe. Fekal was also
better for isolating LT-positive E. coli. The rest of
PLACEBO
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the results probably reflect the fact that using two
specimens increases the probability of isolating en-
teropathogens. Overall, the same pathogen was iso-
lated by both systems in 50% of the cases. The Remel
system allowed the isolation of 70010 of all the patho-
gens that were identified, and the Fekal system al-
lowed the isolation of 80% of the bacterial entero-
pathogens.
Whereas the PVA fixative revealed two infections
with E. histolytica, only one was found by the MF
method. No other pathogenic parasites weredetected
with either of these two methods.
Efficacy of BSS. The time from initiation of
BISMUTH
SUBSALICYLATE
Figure 1. Number and proportion of
stools with the indicated consistency
(_, firm; ma, soft; sa, watery) in the
BSS and in the placebo groups in West
Africa (top) and Mexico (bottom).
Time on the horizontal axis indicates
the hours after initiation of treatment.
PLACEBO
BISMUTH
SUBSALICYLATE
0-12
0-12 12-24 24-36
TIME (HOURS)
TIME (HOURS)
36-48
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therapy to the passage of the last unformed stool was
significantly diminished in West Africa (25.8 h vs.
34.5 h, P < .01) and in Mexico (24.2 h vs. 31.4 h, P
= .02). Also, the time to total relief of all symptoms
after therapy was begun was significantly shortened
by treatment with BSS in West Africa (33.1 h vs. 38.0
h, P = .01), as well as in Mexico (36.0 h vs. 47.5 h,
P < .01). Figure 1 shows the decrease in unformed
stools passed and the improvement in stool con-
sistency over the period of investigation at both study
locations. The active medication reduced the aver-
age-number of unformed stools in the entire study
period by 18070 in West Africa and by 16070 in Mex-
ico. BSS relieved severe illness (i.e., seven or more
bowel movements per day) as favorably as mild ill-
ness. Although the entire disease state was shortened
with BSS therapy, there were insufficient numbers
to observe significant differences for any of the in-
dividual concomitant symptoms, such as abdomi-
nal pain and cramps, nausea, vomiting, or chills. In
West Africa, diarrhea persisting after 48 h of treat-
ment was noted in 21 (31%) of patients receiving BSS
and in 36 (57%) of patients receiving placebo (P
= .01). In Mexico, 8 (16%) of patients treated with
BSS and 21(42%) receiving placebo (P< .01)needed
alternative therapy or had continuing diarrhea at the
end of 72 h of observation.
In West Africa, of the patients treated with BSS,
46% stated they were completely cured at the end
of the 48-h treatment period, whereas only 25% of
the patients receivingplacebo felt their condition had
completely resolved. Similar results were obtained
in Mexico, where the respective rates were 53070 and
39070 after 48 h. These rates of cure were corrobo-
rated by the investigators' evaluation.
BSS was well tolerated at both study sites; no se-
rious adverse reactions occurred. In the total study
population, a black tongue was noted by 25 (22%)
of 116 volunteers receiving BSS and by 5 (4%) of
113 receiving placebo. Black stools were reported by
79 (69%) of those who used BSS and by 12 (11%)
of those receiving placebo. These reactions are an-
ticipated effects of BSS therapy and were mentioned
both in the informed consent and on the diary cards.
The occurrence of a black tongue in individuals in
the placebo group was likely a result of exaggerated
concerns due to our previous warnings. Excluding
such discoloration, no significant differences were
observed between the active treatment and the
placebo group; the number of subjects reporting tin-
nitus was 9 (8%) vs. 4 (4%), and the number report-
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ing constipation was 13 (12%) vs. 19 (18%), respec-
tively.
Discussion
In this first etiologic assessment of travelers' diar-
rhea in West Africa, similar enteropathogens were
found as those reported from Mexico. The only
noteworthy differences were the somewhat higher
proportion of enterotoxigenic E. coli and the occur-
rence of Plesiomonas in West Africa. Compared with
the results of most other studies summarized at the
Consensus Development Conference on Travelers'
Diarrhea [2, 3], pathogens have been isolated in a
high proportion of patients. This may partly be due
to the fact that two specimens werecollected to com-
pare the two transport media. If further studies per-
formed at other destinations in developing countries
confirm the finding that the etiology of travelers' di-
arrhea is more or less the same everywhere, the same
therapeutic regimen applies everywhere.
The use of fecal transport media to assess travelers'
diarrhea has originally been described by Shore et
al. [13] and refined by Morgan et al. [14]. Morgan
et al. [14] provided evidence that conventional entero-
pathogens (enterotoxigenic E. coli and Shigella) were
well preserved in fecal transport media for at least
three weeks. In fact, more Shigella strains were re-
covered by using transport media than by using more
timely direct plating done with thesame stool speci-
mens; BGS and modified CB (Remel)were then used.
In the present study both systems worked well, but
the Fekal system was slightly, but not significantly,
superior. An additional advantage over the Remel
system is that in the Fekal system, no extra vial of
CB is required to isolate C. jejuni. Ideally, multiple
culture systems would be used to optimize the isola-
tion of bacterial pathogens. In view of the small
number of E. histolytica isolated, no conclusions can
be drawn from the comparison of PYA and ME In
a previous study [15] it was shown that formalin-fixed
material yields higher numbers of E. histolytica cysts
than does PYA. Formalin-fixed material was also
clearly superior in diagnostic efficiency for E. coli,
hookworm, and Strongyloides stercoralis. Further-
more, the merthiolate-iodine-formalin concentration
method was more effective for identifying G. lamblia
than was PYA [10]. The availability of commercial
transport systems that efficiently preserve bacterial
and parasitic enteropathogens for later identification
means that field studies are possible in remote areas
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of the world in the absence of local microbiological
facilities.
This study shows that BSS, when taken in a dose
of 4.2 g/d, provides a moderate, but significant, ben-
efit in reducing the duration of diarrheal illness,
reducing the number of unformed stools, and im-
proving the stool consistency in patients with travel-
ers' diarrhea. This finding confirms an earlier trial
[4] in which 4.2 g/d was also shown to be effective,
but even better results were obtained with a higher
dosage. Furthermore, in the present study a similar
beneficial effect, despite different entrance criteria
for disease severity, was noted in Mexico as well as
in West Africa, where the agents' efficacy had not
previously been tested. In the total study population
the average time until the last unformed stool was
reduced by 25% at both study sites; the average time'
until relief from all symptoms was diminished by
14% in West Africa and by 23070 in Mexico.
Taking four or eight doses of BSS within 4 h after
beginning treatment is not convenient when start-
ing late in the evening. Spacing out the frequency
of administration might lead to more convenience
as well as greater efficacy, as similarly found in
prevention studies [16]. A therapeutic regimen giv-
ing BSS every 3 h has been successfully tested in a
pediatric population [17], but this, or possibly a stan-
dard dosage regimen, needs to be confirmed in adult
patients with travelers' diarrhea.
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